TG-1701, a Novel Irreversible Bruton’s Kinase (BTK) Inhibitor, Cooperates with Ublituximab-Driven ADCC and ADCP in In Vitro and In Vivo Models of Ibrutinib-Resistant Mantle Cell Lymphoma

Drug Category : Array
Conference Category : Array
Lead Author : Ribeiro M, et al.
Published Date : 22/06/2020
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2020/06/AACR-Poster-2205_v2.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top